Elevated serum levels of IL-21 in Kawasaki disease

Allergy, Asthma and Immunology Research

Volumn 4, Issue 6, 2012, Pages 351-356

  Bae, Yon Jung ^a   Kim, Mi Hyun ^a   Lee, Hae Yong ^a   Uh, Young ^a   Namgoong, Mee Kyung ^a   Cha, Byung Ho ^a   Chun, Jin Kyong ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Immunoglobulin E; Interleukin 21; Mucocutaneous lymph node syndrome

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN E; INTERLEUKIN 21; INTERLEUKIN 4;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; IMMUNOASSAY; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD;

EID: 84869793407     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2012.4.6.351     Document Type: Article

References (35)

1. Franco A, Shimizu C, Tremoulet AH, Burns JC. Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity 2010;43:317-24.
2. Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics 2005;116:e760-6.
3. Chun JK, Jeon BY, Kang DW, Kim DS. Bacille Calmette Guerin (BCG) can induce Kawasaki disease-like features in programmed death-1 (PD-1) gene knockout mice. Clin Exp Rheumatol 2011;29:743-50.
4. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol 2010;22:551-60.
5. Burns JC. The riddle of Kawasaki disease. N Engl J Med 2007;356: 659-61.
6. Lin CY, Lin CC, Hwang B, Chiang BN. The changes of interleukin-2, tumour necrotic factor and gamma-interferon production among patients with Kawasaki disease. Eur J Pediatr 1991;150:179-82.
7. Furukawa S, Matsubara T, Motohashi T, Sasai K, Nakachi S, Umezawa Y, Yabuta K. Increased expression of Fc epsilon R2/CD23 on peripheral blood B lymphocytes and serum IgE levels in Kawasaki disease. Int Arch Allergy Appl Immunol 1991;95:7-12.
8. Chen Q, Yang W, Gupta S, Biswas P, Smith P, Bhagat G, Pernis AB. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008;29:899-911.
9. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005; 5:688-98.
10. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008;26: 57-79.
11. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R,Leonard WJ, Lipsky PE. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005;175:7867-79.
12. Pène J, Guglielmi L, Gauchat JF, Harrer N, Woisetschläger M, Boulay V, Fabre JM, Demoly P, Yssel H. IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated with a polymorphism in the IL-21R gene. J Immunol 2006;177:5006-13.
13. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008;20:295-301.
14. Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol 2010;162:131-7.
15. Sohn MH, Noh SY, Chang W, Shin KM, Kim DS. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. Scand J Rheumatol 2003;32:364-6.
16. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol 2008;181:1767-79.
17. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33.
18. Leung DY. The immunologic effects of IVIG in Kawasaki disease. Int Rev Immunol 1989;5:197-202.
19. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T, Kawarano M, Baba K, Baba K, Mori C, Joho K, Seto S. Intravenous gamma-globulin for Kawasaki disease. Acta Paediatr Jpn 1991;33:799-804.
20. Lee HK, Kim DS, Noh GW, Lee KY. Effects of intravenous immune globulin on the peripheral lymphocyte phenotypes in Kawasaki disease. Yonsei Med J 1996;37:357-63.
21. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T, Kawarano M, Baba K, Baba K, Mori C. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8.
22. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
23. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A 2000;97:11439-44.
24. Recher M, Berglund LJ, Avery DT, Cowan MJ, Gennery AR, Smart J, Peake J, Wong M, Pai SY, Baxi S, Walter JE, Palendira U, Tangye GA, Rice M, Brothers S, Al-Herz W, Oettgen H, Eibel H, Puck JM, Cattaneo F, Ziegler JB, Giliani S, Tangye SG, Notarangelo LD. IL-21 is the primary common gamma chain-binding cytokine required for human B-cell differentiation in vivo. Blood 2011;118:6824-35.
25. Lee SK, Rigby RJ, Zotos D, Tsai LM, Kawamoto S, Marshall JL, Ramiscal RR, Chan TD, Gatto D, Brink R, Yu D, Fagarasan S, Tarlinton DM, Cunningham AF, Vinuesa CG. B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells. J Exp Med 2011;208:1377-88.
26. Andersen T, Rasmussen TK, Hvid M, Holm CK, Madsen KJ, Jurik AG, Hokland M, Stengaard-Pedersen K, Schiøttz-Christensen B,Deleuran B. Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings. Rheumatol Int 2012;32:387-93.
27. Ott H, Stanzel S, Ocklenburg C, Merk HF, Baron JM, Lehmann S. Total serum IgE as a parameter to differentiate between intrinsic and extrinsic atopic dermatitis in children. Acta Derm Venereol 2009;89:257-61.
28. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007;178:3822-30.
29. Sweet RA, Ols ML, Cullen JL, Milam AV, Yagita H, Shlomchik MJ. Facultative role for T cells in extrafollicular Toll-like receptor-dependent autoreactive B-cell responses in vivo. Proc Natl Acad Sci U S A 2011;108:7932-7.
30. Grunebaum E, Blank M, Cohen S, Afek A, Kopolovic J, Meroni PL, Youinou P, Shoenfeld Y. The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies. Clin Exp Immunol2002;130:233-40.
31. Chun JK, Lee TJ, Choi KM, Lee KH, Kim DS. Elevated anti-alpha-enolase antibody levels in Kawasaki disease. Scand J Rheumatol 2008;37:48-52.
32. Cunningham MW, Meissner HC, Heuser JS, Pietra BA, Kurahara DK, Leung DY. Anti-human cardiac myosin autoantibodies in Kawasaki syndrome. J Immunol 1999;163:1060-5.
33. Gupta M, Johann-Liang R, Bussel JB, Gersony WM, Lehman TJ. Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease. Cardiology 2002;97:180-2.
34. Burns JC, Shimizu C, Shike H, Newburger JW, Sundel RP, Baker AL, Matsubara T, Ishikawa Y, Brophy VA, Cheng S, Grow MA, Steiner LL, Kono N, Cantor RM. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun 2005; 6:438-44.
35. Kuo HC, Wang CL, Wang L, Yu HR, Yang KD. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease. Pediatr Allergy Immunol 2008;19:184-5.